{"entity":{"id":"nct03897881","kind":"trial","name":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN","aka":[],"tldr":"A phase 2 trial of Intismeran autogene, Pembrolizumab in melanoma, run by ModernaTX, Inc., active and no longer recruiting.","summary":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) is a phase 2 interventional study registered as NCT03897881 by ModernaTX, Inc., with 267 participants enrolled, started 2019-07-18 and due to reach its primary completion in 2032-11-21. Interventions recorded: mRNA-4157, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03897881","url":"https://clinicaltrials.gov/study/NCT03897881"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["intismeran-autogene","pembrolizumab"],"companies":["moderna"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-942-lancet-2024","paper-nct03897881-j-clin-oncol-2026-update"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03897881","phase":"2","setting":"A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)","sponsor":"ModernaTX, Inc.","started":"2019-07-18","startedType":"actual","enrolled":267,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03897881/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/"}],"paper":[{"id":"paper-nct03897881-j-clin-oncol-2026-update","kind":"paper","name":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","route":"/key-papers/paper-nct03897881-j-clin-oncol-2026-update/"},{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/"}]}}